A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Schizophrenia Clinical Trial

Official title:

A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03713658
• Other study ID #: CR108551
• Secondary ID: R092670PSY4001
• Status: Completed
• Phase: Phase 4
• Start date: October 18, 2018
• Est. completion date: December 2, 2019

Study information

• Verified date: February 2024
• Source: Janssen Research & Development, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 2, 2019
• Est. primary completion date: December 2, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Participants with diagnosis of schizophrenia by mini international neuropsychiatric interview (MINI)- Screen/ MINI (Module K) that requires treatment initiation or a change in treatment to better address safety or efficacy limitations of current treatment
• Participants at least moderately ill as measured by the clinical global impressions - severity of schizophrenia (CGI-SS) scale for schizophrenia, or experiencing poorly tolerated side effects from their current medications, or having difficulty with adequate adherence to treatment, per the investigator's judgement
• Participants have a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition and is expected to be with the participant for greater than (>) 24 hours each week for the duration of the study)
• Participants able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
• Participants must be willing and able to provide responses for all self-administered questionnaires

Exclusion Criteria:

• Participants have a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
• Participants with history of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
• Participants with known allergies, hypersensitivity, or intolerance to risperidone or paliperidone palmitate or their excipients
• Participants with poor prior response to risperidone
• Participants who received an investigational medication (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication, or is currently enrolled in an investigational study

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• Risperidone 3 mg
Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
• Paliperidone Palmitate 50 mg eq.
Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
• Paliperidone Palmitate 75 mg eq.
Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
• Paliperidone Palmitate 100 mg eq.
Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
• Paliperidone Palmitate 150 mg eq.
Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
• Paliperidone Palmitate 175 mg eq.
Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
• Paliperidone Palmitate 263 mg eq.
Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
• Paliperidone Palmitate 350 mg eq.
Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
• Paliperidone Palmitate 525 mg eq.
Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.

Locations

Country	Name	City	State
Rwanda	CARAES Ndera Neuro-Psychiatric Hospital	Kigali
Rwanda	Ruhengeri Referral Hospital, Public Hospital	Musanze District
Rwanda	Kibungo Referral Hospital	Ngoma District

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

Rwanda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Successful Completion of Study Procedures	Percentage of participants with successful completion of study procedures related to diagnosis and outcome measures assessment will be reported.	Up to Week 46
Primary	Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the Study	Percentage of participants with successful delivery of risperidone/PP1M/PP3M for the duration of the study will be reported.	Up to Week 46
Primary	Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the Study	Percentage of participants with successful administration of risperidone/PP1M/PP3M throughout the study will be reported.	Up to Week 46
Primary	Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total Score	The WHO QoL-BREF is a 25 item scale used to assess the quality of life. All items are rated on a five-point likert scale using response categories such as 1 represents very poor and 5 represents very well with a possible maximum score of 125 and a minimum score of 25.	Up to Week 46
Primary	Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale Score	The Clinician Satisfaction Rating is a 4-item scale. Two items use a Likert scale with a six-point range from 0 (definitively not) to 6 (definitely) and two items are multiple-choice (example, "select all that apply"). The scale will be used to assess the acceptability and/or burden for the provider associated with the study including treatment with long-acting injectables (LAIs).	Up to Week 46
Secondary	Number of Participants Who Met Mini-International Neuropsychiatric Interview (MINI)-MINI Screen and Module K Criteria	The MINI-Screen is a structured and standardized diagnostic interview used to determine the most common psychiatric disorders according to axis I diagnostic and statistical manual of mental disorders-fourth edition text revision (DSM-IV-TR) and the international classification of diseases and related health problems (ICD-10). The MINI-screen will be administered to participants for preselection by a qualified psychiatric professional. If this step is passed, then Module K of MINI will be applied by a medical doctor (preferably a psychiatrist) or a psychologist in order to confirm the diagnosis of schizophrenia and to determine if there are other psychiatric conditions present. Number of participants who met MINI criteria will be assessed.	Up to Week 46
Secondary	Number of Participants Intended to Complete/Attend Next Visit as Assessed by Intent-to-Attend (ITA) Plus Assessment Scale	The ITA-Plus scale is a single Likert scale question with a range of 0 indicates definitely not attending to 6 indicates definitely attending that will be used to estimate the likelihood of completing the study or attending the next visit to provides qualitative feedback on why completion/attendance may not occur. Number of participants intended to complete/attend next visit will be assessed.	Up to Week 46
Secondary	Direct Cost Assessment of Schizophrenia Care as Assessed by Client Service Receipt Inventory (CSRI) Scale Score	The CSRI scale will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially direct costs.	Up to Week 46
Secondary	Indirect Cost Assessment of Schizophrenia Care as Assessed by Cost Assessment Questionnaire (CAQ)	The CAQ will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially indirect costs.	Up to Week 46
Secondary	Change From Baseline in Sheehan Disability Scale (SDS) Total Score	SDS will be used to assess the functioning of participants with schizophrenia. It has participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0 (no impairment) - 10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement.	Baseline up to Week 46
Secondary	Number of Participants With Adverse Events (AEs) as a Measure of Safety	Safety will be assessed by AEs along with concomitant medications, past medical history, and demographics of participants who will participate in this study. An adverse event is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the medication. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.	Up to Week 46
Secondary	Psychosis as Assessed by Mental Illness With Lay Evidence (SMILE) Scale Score	The Psychosis module of the SMILE will be used to assess the clinical symptoms of schizophrenia. It is a 15-item Likert scale covering questions to describe participants condition like if they have kept the body neat and clean, difficulty in completing routine tasks, talked to themselves etc with answers on a point range of 0 (Never) to 5 (All the time). It uses 7-day recall period. Both the participant and caregiver participant will complete this scale.	Up to Week 46
Secondary	Clinical Global Impression - Severity of Schizophrenia (CGI-SS) Scale Total Score	The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (0 indicates none to 7 indicates extreme symptoms).	Up to Week 46

External Links

•   A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda